Altshuler Shaham’s Keros Therapeutics KROS Stock Holding History

Altshuler Shaham’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-34,074	Closed	-$941K	–	503
2022 Q2	$941K	Sell	34,074 -789	-2%	-$34.6K	0.01%	79
2022 Q1	$1.9M	Sell	34,863 -10,500	-23%	-$539K	0.02%	121
2021 Q4	$2.64M	Hold	45,363	–	–	0.02%	112
2021 Q3	$1.8M	Buy	45,363 +22,847	+101%	+$813K	0.01%	139
2021 Q2	$957K	Hold	22,516	–	–	0.01%	172
2021 Q1	$1.39M	Hold	22,516	–	–	0.01%	89
2020 Q4	$1.59M	Sell	22,516 -3,030	-12%	-$191K	0.03%	58
2020 Q3	$985K	Buy	+25,546	New	+$1.01M	0.02%	74

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Altshuler Shaham's KROS Position: Q3 2022 in Review

Altshuler Shaham sold out of Keros Therapeutics (KROS) in Q3 2022, closing a stake of 34,074 shares — an estimated $941K sold.

Altshuler Shaham first reported a position in KROS in Q3 2020 and held it in 8 quarters. The position peaked at $2.64M in Q4 2021. 113 funds tracked by Wall St. Rank hold KROS as of Q3 2022.

Altshuler Shaham reported no remaining Keros Therapeutics position as of Q3 2022 after selling out during the quarter.
Altshuler Shaham sold 34,074 Keros Therapeutics shares in Q3 2022, an estimated $941K.
Altshuler Shaham first reported a position in Keros Therapeutics in Q3 2020 and held it in 8 quarters.
Altshuler Shaham's Keros Therapeutics position peaked at $2.64M in Q4 2021.
113 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2022.

Based on Altshuler Shaham's 13F filing for Q3 2022, filed 14 Nov 2022.